Grows a rare semiconductor crystal and turns it into detectors that identify radioactive isotopes for hospitals and border security.
At a glance
- Depends onUpstream position: supplies 3 industries, depends on 0
- Scale
Grows a rare semiconductor crystal and turns it into detectors that identify radioactive isotopes for hospitals and border security.
What this company is and how it runs — written from structure, not news.
Kromek Group grows its own cadmium zinc telluride crystals in Bridgman furnaces and turns them into gamma-ray detector arrays that can tell one radioactive isotope apart from another — a capability that silicon detectors cannot match and that both NHS cardiac imaging systems and border security portals depend on. Because the crystal's purity is what makes that isotope separation possible, the whole fabrication process runs in a semiconductor-grade cleanroom, and the resulting detectors are certified under ISO 13485 medical device rules and UK Export Control Office licences that tie each approval to a specific detector model built from internally characterised crystal batches. A hospital or border agency that switched to a different supplier's detectors would have to revalidate their own system certifications from scratch, which keeps customers locked to Kromek's specific detector models rather than to detector technology in general. The ceiling on how fast the company can grow is set by how many Bridgman furnaces it runs and what fraction of each crystal boule clears the quality threshold — no amount of engineering removes that yield floor entirely, so crystal output, not demand, is what bounds production.
How does this company make money?
The company earns money each time it sells a detector module or a complete imaging system. It also collects recurring revenue from calibration services and from replacement detectors, because radiation exposure gradually damages CZT arrays over time and they must eventually be swapped out.
What makes this company hard to replace?
Switching to a different supplier's detectors means recalibrating gamma-ray energy libraries and revalidating the entire system against those new response characteristics. Medical device approvals link specific CZT detector models directly to the imaging system certifications that hospitals operate under, so swapping the detector can invalidate the hospital system's own certification. Security screening protocols are validated for the specific way a given detector responds to gamma rays, and a different detector's response profile would require the protocol to be revalidated from scratch.
What limits this company?
Every CZT crystal grown in a Bridgman furnace contains natural defects that cannot be engineered away entirely. Only the portion of each crystal that clears a minimum purity threshold can become a working detector. That means total detector output is capped by how many furnaces are running and by how much of each crystal is good enough to use — adding more furnaces helps, but the underlying yield floor stays.
What does this company depend on?
The company cannot operate without cadmium and tellurium feedstock to grow its crystals, Bridgman furnaces capable of processing CZT and CdTe, ASIC readout electronics qualified to work in radiation environments, ISO 13485 medical device certification for its imaging products, and UK Export Control Office licences to sell radiation detection technology internationally.
Who depends on this company?
NHS hospitals running CZT-based cardiac SPECT systems would lose the ability to distinguish a medical tracer isotope from background radiation in myocardial perfusion studies. UK Border Force gamma-ray portal monitors would lose the ability to separate medical isotopes — carried by patients who recently had scans — from weapons-grade material. Nuclear power plant operators would lose real-time gamma spectroscopy for monitoring reactor coolant.
How does this company scale?
Software for gamma-ray spectroscopy and detector calibration can be copied to every unit sold at almost no extra cost. What does not scale easily is the crystals themselves: Bridgman furnace throughput is finite, and the yield floor that discards defective portions of each boule cannot be removed by engineering, so crystal supply stays the hard ceiling on growth.
What external forces can significantly affect this company?
US-China technology export restrictions limit which countries the company can sell radiation detection systems to. NHS procurement budget pressures can slow or reduce UK medical imaging equipment purchases. Post-Brexit trade arrangements create friction in selling dual-use detection technology through European sales channels.
Where is this company structurally vulnerable?
If the UK Export Control Office tightened the rules on CZT detector licences — for example by demanding stricter proof that each detector was built from a specific approved crystal batch, or by reclassifying certain detector grades — the company would have to restart its certification process from the crystal level upward. During that revalidation period it could not legally ship certified product, and the same vertical integration that keeps competitors out would trap the company inside a long re-approval queue.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Three observations have aligned in the up direction: the Ichimoku-cloud composite is firing on its up-side configuration, the trend-strength composite is in the upper portion of its mapped range, and the volume-weighted-returns sum over the 60-week lookback is net positive.
Two structural conditions align: (1) a multi-year price band exists where the stock has, on at least two separated occasions, stopped advancing and pulled back, and (2) current price is back inside or just below that zone, near the top of its recent trading range. The retest is happening at a level the stock has reached before and turned away from.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph